Intravesical drug delivery strategies for NMIBC

A permanent J code helps standardize billing and clarifies expected payment levels, often embedding reimbursement terms into payer contracts.

Rubenstein emphasizes the importance of strong clinical documentation and preparation by billing teams.

“Once we actually get a J code for a medication, it really solidifies the amount of reimbursement that's going to occur,” says Jonathan Rubenstein, MD.

Christopher M. Pieczonka, MD, discusses practical strategies to optimize tolerability and minimize early discontinuation with indwelling intravesical drug-releasing systems for bladder cancer.

David Morris, MD, FACS, discusses expert panel recommendations on intravesical drug-releasing systems in bladder cancer, highlighting early drug release dynamics, tolerability, and optimizing patient comfort.